Evaluate Custom Solutions

Custom Solution Image 1

Evaluate Custom Solutions(カスタムソリューション)では、プロジェクト専門チームがお客様の課題に柔軟に対応し、客観性と専門性のある分析や洞察をご提供します。

お客様の研究開発や経営の戦略的意思決定に役立つ情報を、EvaluatePharmaの全てのデータセットに加えテーラーメイド型分析手法や各種調査などを総動員し、ご提供します。

お問い合わせはこちら

Testimonials

Evaluate Custom Solutions paid careful attention to our report needs, and the after-care service was excellent, so our level of satisfaction was extremely high. It was one of the best services that I have experienced so far.

Motomu Himori, Specialist, Chugai Pharmaceutical Co., Ltd.

I really could not do my job without Evaluate data. You guys make me look good all the time.

Business Development & Licensing, Large Pharmaceutical

Our Work & Case Studies

Over the last year, 13 of the world’s largest pharmaceutical and biotech companies have engaged Evaluate Custom Solutions in addressing their biggest global challenges. These clients have engaged us to provide insight to help inform a range of their key objectives including: Market Analysis & Competitor Intelligence, Corporate Strategy & Franchise Planning, Market Expansion & Forecasting, Mergers & Acquisition, New Product Development, Market Access and Pricing & Commercialization.

Below are some examples of the work we have undertaken for the likes of Abbvie, Amgen, AstraZeneca, Bayer, Daiichi Sankyo, Gilead, GSK, Johnson & Johnson/Janssen, Merck KGaA, Novartis, Pfizer, Roche/Chugai and Sanofi.

User circle 1
経営戦略部門向け

お客様を取り巻く市場環境・競合状況・戦略的方向性などについて、お客様側の視点に加え、第三者の客観的視点で業界を分析した情報を加えることをお勧めします。

事例 - 大手グローバル製薬会社クライアント

当社サービスによる第三者視点としての市場動向分析を、経営戦略策定会議にて活用されています。

User circle 1
研究開発企画 & ポートフォリオ戦略部門向け

お客様の製品ポートフォリオを客観的に検証するために、第三者機関として当社をご利用いただけます。

事例 - 日本の製薬企業クライアント

研究開発の生産性について、自社と競合他社をベンチマークし潜在的な傾向や成功/失敗要因を把握するために当社サービスを活用しています。

User circle 1
デジタル化 & データサイエンスに関わる部門向け

業界を代表する当社の各種分析データを、データフィードやAPIによってお客様の社内ツール、システム、ワークフローに直接組み込むことも可能です。

事例 - 米国の大手製薬企業クライアント

M&A候補スクリーニングツールとして、当社データを組み込んだダッシュボード(データ更新型可視化ツール)を開発し、活用しています。

User circle 1
コマーシャルオペレーション、プライシング & 市場予測に関わる部門向け

疫学調査、売上予測モデル、薬価分析においてニーズに合わせた調査分析やモデル構築を行い、お客様の製品戦略に役立てていただけます。

事例 - 製薬企業クライアント

全社製品に標準的に適用できる売上予測モデルを当社サービスによって構築し、コマーシャル部門およびファイナンス部門がこれを利用しています。

User circle 1
事業開発 & ライセンシング部門向け

パートナリングやライセンスイン、アセット売却に向けた調査・スクリーニング作業の迅速化を当社はサポートします。

事例 – 中規模の製薬企業クライアント

当社ソリューションサービスを利用してライセンシング候補となる他社アセットリストを入手し、調査・スクリーニング作業を効率化しています。

User circle 1
バイオテク & 小規模製薬企業の経営陣向け

製品の開発戦略策定に必要な、対象疾患の患者数、アンメットニーズ、製品ポジショニングのシナリオなどの情報分析を当社にご依頼いただけます。

事例 – バイオテク経営陣であるクライアント

自社のリードアセットの臨床およびビジネス上のポジショニングを検討・評価するために当社ソリューションサービスを利用しています。

Our Services

Our services are designed for teams defining product and portfolio strategy and setting direction for key brands and franchises.  We provide insight into Market Analysis & Competitor Intelligence, Corporate Strategy & Franchise Planning, Market Expansion & Forecasting, Mergers & Acquisition, New Product Development, Market Access and Pricing & Commercialization. 

Leveraging a foundation of extensive Evaluate data augmented with further secondary research, modelling, and analysis, our solutions are data-driven and insight-focused.  We also conduct targeted primary research with Key Opinion Leaders, Healthcare Professionals and Payers to validate our assumptions and test our hypotheses.  

Below we have provided an overview of our services and how they apply to the life stages of companies / products. Please click on the “+” to find out more.  If there is something that is not listed here please contact us so we can work with you to get you the insights you need.
 

Discovery & Preclinical
Early Clinical Development (P1-P2a)
Late Clinical Development (P2b-P3)
Commercialisation

Market Analysis & Competitive Intelligence

Industry trend & growth driver analysis

Productivity & return on investment benchmarking

Indication landscape & evolution analysis

Competitor strategy profiling

Competitive landscape evolution and outlook

Epidemiology Modelling & Systematic Literature Review

Burden of illness & incidence/prevalence studies

Global/regional/country-specific patient segmentation modelling

Standard of care & treatment paradigm definition

Clinical outcomes & treatment pattern studies

Market sizing & unmet need identification

Oncology patient dynamic flow modelling

Rare disease epidemiology

Opportunity Identification & Quantification

Market profiling & segment analysis

Indication sizing, scoring & prioritisation

Competitive intensity analysis

Market opportunity analysis & forecasting

Opportunity identification, fit & prioritisation assessment

BD&L target search, screen & assessment

Partner identification & profiling

Deal benchmarking analysis

Product Strategy & Differentiation

Niche identification & addressable population sizing

Product positioning & differentiation assessment

Target product profile (TPP) definition & testing

Price benchmarking & sensitivity analysis

Scenario-based sales & volume forecast modelling

Product targeting & development strategy assessment

Data Feeds & APIs

Programmatic access to Evaluate data

Resources

Establishing the prevalence of rare diseases from published literature

The focus of drug development has shifted in the last 10 years to treatment of rare diseases. This has largely been driven by the payer environment. According to the NIH, there are over 7,000 rare diseases (many being sub-sets of larger diseases), many of which have not been quantified to date. 

This lack of solid epidemiology data poses something of a problem when it comes to being able to value an asset for a rare disease. This paper provides a best practice perspective on how to establish the prevalence of rare diseases.
 

Asset valuations in Healthcare

Healthcare is a heavily specialist arena and it is not always obvious how an asset should be valued. Creating valuations or forecasts that are fit for purpose, appropriately detailed and represent an accurate consideration of true drivers of the market is both an art and a science.   

This paper provides a perspective on how to build best practice Asset Valuations. 
 

Essentials for robust Oncology forecasting and market valuations

The foremost thing you need to know about forecasting in the oncology area is that you will most likely be dealing with a highly dynamic therapeutic area with its own peculiarities.

Most analysts when faced with an oncology forecast can find it quite daunting since oncology is a highly specialised and technical area mixed in with plenty of seemingly impenetrable terms. These nuances are discussed and broken down into bite sized chunks that can be digested more easily.